Particular individuals are more responsive to CAR T cell therapy than others. This could be due to heterogeneity in the CAR T infusion product or to a difference in the patients body immune system. Scientist at first used flow cytometry or bulk RNA sequencing to define endogenous immune cells and healing CAR T cells, however these methods do not have the solving power needed to profile all immune cell types and states present in the population. The introduction of single-cell transcriptomics has actually allowed scientists to deeply profile complicated cell populations to refine the infusion item and tailor it to the patient.Download this white paper from 10x Genomics to discover how targeted single-cell transcriptomicsAnalyzes transduction effectiveness in specific restorative cellsDetects and identifies CAR T cell heterogeneityConnects a cells transcriptome to its practical stateSponsored by
